RBC Capital Maintains Outperform on Sarepta Therapeutics, Raises Price Target to $223
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Brian Abrahams maintains an Outperform rating on Sarepta Therapeutics (NASDAQ:SRPT) and raises the price target from $221 to $223.
August 04, 2023 | 1:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital maintains an Outperform rating on Sarepta Therapeutics and raises the price target from $221 to $223.
The news of RBC Capital maintaining an Outperform rating and raising the price target for Sarepta Therapeutics is likely to instill confidence in investors and could potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100